sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Situ Hybridization: Market Shares, Strategy, and Forecasts, Worldwide, 2018 to 2024

Situ Hybridization: Market Shares, Strategy, and Forecasts, Worldwide, 2018 to...

Home / Categories / Energy and Power
Situ Hybridization: Market Shares, Strategy, and Forecasts, Worldwide, 2018 to 2024
Situ Hybridization: Market Shares, Strategy,...
Report Code
RO6-104-1001

Publish Date
28/Feb/2018

Pages
242
PRICE
$ 4300/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 8600/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..

Abstract:  In Situ Hybridization Reagents Make It Possible To Visualize Expression Of Virtually Any Gene In Individual Cells While Retaining Valuable Tissue Morphology Information 1


Table of Contents 3


US In situ Hybridization Executive Summary 15


In Situ Hybridization (ISH) 15


1. United States In Situ Hybridization ISH Market Definition and Market Dynamics 16


1.1 US In situ Hybridization Market Overview 16


1.1.1 Antibody Challenges and Validation 16


1.2 Scope of In situ Hybridization in Inflammation 17


1.2.1 RNAscope Applications 17


2. In-Situ Hybridization Market Shares and Market Forecasts 20


2.1 In-Situ Hybridization Market Driving Forces 20


2.1.1 Identification of Cytokines and their Cellular Origins 21


2.1.2 Detection of Long Non-Coding RNA (lncRNA) in Inflammatory Diseases 21


2.1.3 Role of Inflammatory Pathways During Carcinogenesis 22


2.1.4 Therapeutic Potential Of Secreted Proteins In Inflammatory Diseases 22


2.1.5 Dual ISH-IHC Detect Cytokines During Inflammatory Responses 22


2.2 In Situ Hybridization Market Shares 24


2.2.1 Roche 25


2.2.2 Abbott Molecular 25


2.2.3 Advanced Cell Diagnostics 25


2.2.4    PerkinElmer In Situ Hybridization Market Driving Forces 26


2.2.5 In Situ Hybridization Market Shares Unit Shipments and Kit Shipments 27


2.3 In Situ Hybridization Market Forecasts 29


2.3.5 In Situ Hybridization Market Segments Units and Kits Dollars and Percent US 29


2.4 In situ Hybridization Market Segments 31


2.4.1 In Situ Hybridization Market Shares Dollars Worldwide 2012 to 2017 32


2.4.2 Fluorescence (FISH) and Chromogenic (CISH) Detection 33


2.4.3 ISH Applications 36


2.4.4 Multiplex Fluorescence In Situ Hybridization (FISH) 36


2.4.5 Fluorescence In Situ Hybridization (FISH) 37


2.4.6 Cancer Drug Market 40


2.4.7 Chronic Lymphocytic Leukemia (CLL) 40


2.4.8 In-Situ Hybridization Cancer Diagnosis Cytology Infectious Disease Molecular Diagnostic 42


2.1.6 In Situ Hybridization Market Segments Diagnostic Laboratories Academic & Research Institutes Contract Research Organizations and Pharmaceutical & Biotechnology Companies 47


2.5 In-Situ Hybridization Pricing 54


2.5.1 miRCURY LNA miRNA Detection Probes 54


2.5.2 Price and Availability 58


2.6 In-Situ Hybridization Geographical Analysis 61


3 In-Situ Hybridization Research and Technology 68


3.1 Hybridization Technique 68


4 In-Situ Hybridization Company Profiles 69


4.1 Abbott Laboratories 69


4.1.1 Abbott Laboratories Market Categorization 69


4.1.2 In Situ Hybridization Product Category Application and Specification 70


4.1.3 Abbott Laboratories Vysis Chronic Lymphocytic Leukemia (CLL) FISH Probe Kit (IVD) 71


4.1.4 Vysis CLL FISH Probe Kit Contents 72


4.1.5 Acupath Laboratories Test For Detecting Bladder Cancer Uses Probes from Abbott Molecular 74


4.1.6 Abbott Laboratories Barrett’s Esophagus FISH 75


4.1.7 Abbott Molecular Vysis CLL FISH Probe Kit | 77


4.1.8 Abbott Laboratories Revenue 77


4.1.9 Abbott Laboratories ThermoBrite System 81


4.1.10 Abbott Laboratories User Programmable Settings 82


4.1.11 Abbott Laboratories Vysis FISH Chromosome Search 83


4.1.12 Abbott Laboratories Molecular Diagnostics 84


4.1.13 Abbott Diagnostic Products 85


4.2 Acupath Laboratories 87


4.2.1 Acupath Laboratories Barrett’s Esophagus FISH 88


4.3 Agilent Technologies 88


4.3.1 Agilent CGH & CGH+SNP Microarrays 91


4.3.2 Agilent Technologies Revenue 91


4.3.3 Agilent Diagnostics and Genomics 93


4.4 Bio-Techne / ACD 96


4.4.1 Bio-Techne ACD RNAscope Widely Used In-Situ Hybridization Technique 97


4.4.2 Bio-Techne Revenue 98 4.4.3 Biotechne US Regional Analysis 101


4.4.4 Advanced Cell Diagnostics 102


4.5 F. Hoffmann-La Roche AG 102


4.5.1 Roche Gene Amplification by Fluorescence In Situ Hybridization 104


4.5.2 Roche Automated RNA isolation 105


4.5.3 Roche Fluorescence In Situ Hybridization (FISH) 105


4.5.4 Roche Agreement with Merck Millipore Sigma 106


4.5.5 Roche Immuno Diagnostics 108


4.5.6 F. Hoffmann-La Roche AG Revenue 109


4.5.7 Roche Buys Flatiron Health Leader In Oncology-Specific Electronic Health Record (EHR) Software 114


4.6 Danaher / Leica Biosystems Nussloch GmbH 115


4.6.1 Leica Biosystems Nussloch GmbH BOND IHC/ISH Instruments 116


4.6.2 Leica Biosystems Nussloch GmbH Revenue 122


4.6.3 Danaher Geographical Revenue 124


4.7 Thermo Fisher Scientific 125


4.7.1 Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH) 125


4.7.2 Chromogenic In Situ Hybridization (CISH) 128


4.7.3 Thermo Fisher Scientific Revenue 133


4.8 Merck KGaA 134 4.9 PerkinElmer 135


4.9.1 PerkinElmer Stain 144


4.9.2 Perkin Elmer Revenue 146


4.10 Qiagen / Exiqon A/S 150


4.10.1 Qiagen’s GeneReader NGS System 153


4.10.2 Polygenetic Mutations Drive Cancer 153


4.10.3 Qiagen Revenue 154


4.11 BioGenex Laboratories 155


4.11.1 BioGenex Fully-Automated Molecular Pathology Workstation 156


4.11.2 BioGenex Boosts Genome Research and Diagnostics - BioGenex US 159


4.11.3 BioGenex Antibodies for Cancer Diagnosis 161


4.11.4 BioGenex PMS2 161 CK5 162


4.11.5 eFISHiency System for the Analysis of Solid Tumors - BioGenex US 163


4.12 Bio SB 165 4.12.1 Bio SB Zytovision Molecular Diagnostics 165


4.13 Bio-Techne / Advanced Cell Diagnostics (ACD) 167


5 Summary and Conclusions 172


5.1 Analyze A Marker At The Single Cell Level 172


5.2 Advances in RNA In Situ Hybridization 172


6 Appendix A: List Of Nucleic Acid-Based Tests 173


6.1 List: Nucleic Acid-Based Tests Approved by US Center for Devices and Radiological Health 173


6.1.1 List of Human Genetic Tests 174


6.1.2 List of Microbial Tests 191


6.2 In Vitro Diagnostics 233


WinterGreen Research 235


WinterGreen Research Methodology 236


WinterGreen Research Process 237


Market Research Study 238


WinterGreen Research Global Market Intelligence Company 239   


 


Abstract:  In Situ Hybridization Reagents Make It Possible To Visualize Expression Of Virtually Any Gene In Individual Cells While Retaining Valuable Tissue Morphology Information 1


Figure 1. In Situ Hybridization Market Shares Dollars US 2016 and 2017 24


Figure 2. In Situ Hybridization Market Driving Forces 26


Figure 3. In Situ Hybridization Market Shares Unit Shipments and Kit Shipments Units and Dollars US 2017 27


Figure 4. In Situ Hybridization Market Shares $ per Unit and $ per Kit Dollars and Percent US 2017 28


Figure 5. In Situ Hybridization Market Segments Unit Shipments and Kit Shipments Units and Dollars US 2017 29


Figure 6. In Situ Hybridization Market Segments $ per Unit and $ per Kit Dollars and Percent US 2017 30


Figure 7. In Situ Hybridization Market Shares Dollars Worldwide 2012 to 2017 32


Figure 8. In Situ Hybridization Market Segments Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) US 2012 to 2017 33


Figure 9. In Situ Hybridization Market Segments Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH) US 2017 to 2024 34


Figure 10. Thermo Fisher Scientific Characteristics of In Situ Hybridization Methods 35


Figure 11. Diagnostics Growth 42


Figure 12. In Situ Hybridization Market Segments Cancer Chromosonal Abnormalities Infectious Diseases Dollars US 2012 to 2017 43


Figure 13. In Situ Hybridization Market Segments Cancer Chromosonal Abnormalities Infectious Diseases Dollars US 2017 to 2024 44


Figure 14. In Situ Hybridization Market Segments Cancer Chromosonal Abnormalities Infectious Diseases Percent US 2017 to 2024 45


Figure 15. In Situ Hybridization Market Segments Cancer Chromosonal Abnormalities Infectious Diseases Percent US 2012 to 2017 45


Figure 16. In Situ Hybridization Market Segments Diagnostic Laboratories Academic & Research Institutes Contract Research Organizations and Pharmaceutical & Biotechnology Companies Dollars US 2012 to 2017 47


Figure 17. In Situ Hybridization Market Segments Diagnostic Laboratories Academic & Research Institutes Contract Research Organizations and Pharmaceutical & Biotechnology Companies Dollars US 2017 to 2024 48


Figure 18. In Situ Hybridization Market Segments Diagnostic Laboratories Academic & Research Institutes Contract Research Organizations and Pharmaceutical & Biotechnology Companies Percent US 2012 to 2017 49


Figure 19. In Situ Hybridization Market Segments Diagnostic Laboratories Academic & Research Institutes Contract Research Organizations and Pharmaceutical & Biotechnology Companies Percent US 2017 to 2024 50


Figure 20. 575 Million People with Autoimmune Disease 51 Figure 21. PerkinElmer Assays for Autoimmune Disease 52


Figure 22. PerkinElmer Diagnostics 53


Figure 23. PerkinElmer In Situ Hybridization 57 Figure 24. In Situ Hybridization Regional Analysis US:  West Rocky Mountain Southwest Midwest South Middle Atlantic New York and New England Percent 2012 – 2017 63


Figure 25. In Situ Hybridization Regional Analysis US:  West Rocky Mountain Southwest Midwest South Middle Atlantic New York and New England Percent 2017 - 2024 65


Figure 26. Abbott Laboratories Vysis CLL FISH Probe Kit Probe Info 71


Figure 27. Abbott Laboratories Vysis CLL FISH Probe Kit Contents 72


Figure 28. Abbott Laboratories Vysis CLL FISH Probe Kit includes LSI 72


Figure 29. Abbott Vysis CLL FISH Probe Kit 73


Figure 30. Abbott Laboratories Segment Sales 2017 78


Figure 31. Abbott Segment Sales 2015-2017 79


Figure 32. Abbott Geographical Revenue 80


Figure 33. Abbott Laboratories ThermoBrite System 81


Figure 34. Abbott Laboratories ThermoBrite System Functions 82


Figure 35. Abbott Laboratories Molecular Testing 84


Figure 36. Abbott Diagnostic Product Target Markets 85


Figure 37. Abbott Diagnostic Principal Products 86


Figure 38. In Situ Hybridization Detection System:  Agilent Product Area: Standard Nucleic Acid Detection System 88


Figure 39. PNA ISH Detection Kit Product Area: PNA Probes & Detection System 90


Figure 40. Roche RNA Isolation Kit 105


Figure 41. Merck MilliporeSigma and Sigma-Aldrich and Roche Offerings 107


Figure 42. Key points of the Roche Merc agreement include: 107


Figure 43. Roche Immuno Diagnostics DISCOVERY XT 108 Figure 44. Roche DISCOVERY XT Research Instrument Functions 109


Figure 45. F. Hoffmann-La Roche AG Sales 110


Figure 46. Roche by the Metrics 112


Figure 47. F. Hoffmann-La Roche AG Pharmaceutical Sales 113


Figure 48. Danaher Brands 116


Figure 49. Leica Biosystems Bond III Technical Specifications 117


Figure 50. Leica Biosystems Nussloch GmbH BOND IHC/ISH Instruments 118


Figure 51. Leica SCN400 Slide Scanner Features 119


Figure 52. Leica BOND Ready-To-Use Antibodies (No Mixing Titration Or Dilution) 120


Figure 53. Leica Biosystems 121 Figure 54. Danaher Segment Revenue 123


Figure 55. Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH) Positioning 125


Figure 56. Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH) In Situ Hybridization (ISH) Technologies 126


Figure 57. Thermo Fisher Scientific Characteristics of In Situ Hybridization Methods 127


Figure 58. 5.7.1 Thermo Fisher Scientific EVOS Cell Imaging Systems 129


Figure 59. Thermo Fisher Scientific Fluorescence Systems 130


Figure 60. Thermo Fisher Scientific Cell Analysis 131


Figure 61. Thermo Fisher Scientific Imaging Portfolio Components 132


Figure 62. Thermo Fisher Scientific Revenue 133


Figure 63. PerkinElmer In Situ Hybridization 136


Figure 64. PerkinElmer In Situ Hybridization 137


Figure 65. PerkinElmer In Situ Hybridization 139


Figure 66. PerkinElmer Financials at a Glance 140


Figure 67. PerkinElmer Diagnostics Revenue 141


Figure 68. PerkinElmer in situ hybridization Expanding Diagnostics Market Reach and Global Impact 142


Figure 69. PerkinElmer Diagnostics 143


Figure 70. PerkinElmer Stain 144 Figure 71. Perkin Elmer Revenue 146


Figure 72. PerkinElmer offers Ultra-Sensitive And Specific Mirna Detection By In Situ Hybridization (ISH) Functions 149


Figure 73. miRCURY LNA miRNA Detection Probes 151


Figure 74. BioGenex Performance Systems 156


Figure 75. BioGenex Product Areas 157


Figure 76. BioGenex Performance Systems / BioGenex Flagship Products 157 Figure 77. BioGenex Customers 158


Figure 78. Figure: Colon Carcinoma stained with PMS2 (clone EP51)Staining in FFPE tisues using DAB chromogen and BioGenex Polymer-HRP Detection System. 162


Figure 79. BioGenex Cervical Cancer Stained with Anti-Human CK-5 (clone EP24)Staining in FFPE Tissues Using DAB Chromogen and Polymer-HRP Detection System 163


Figure 80. BioGenex Fish Steps Reduction 164


Figure 81. BioGenex eFISHiency System Reduces Hands-On Processing Time To 30 Minutes 165


Figure 82. Bio SB Zytovision Molecular Diagnostics 165


Figure 83. Bio-Techne / ACD 170

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com